Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Baxter
Colorcon
Fish and Richardson
Deloitte
Teva

Generated: August 21, 2019

DrugPatentWatch Database Preview

Claims for Patent: 8,008,335

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,008,335
Title:Indole and benzimidazole derivatives
Abstract: The present invention relates to new indole and benzimidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula (I).
Inventor(s): Boyce; Rustum S. (Singapore, SG), Xia; Yi (Palo Alto, CA), Guo; Hongyan (San Mateo, CA), Mendenhall; Kris G. (Concord, CA), Walter; Annette O. (Mill Valley, CA), Wang; Weibo (Moraga, CA)
Assignee: Novartis Vaccines and Diagnostics, Inc. (Emeryville, CA)
Application Number:11/665,956
Patent Claims:1. A compound of formula I: ##STR00092## wherein: W is .dbd.CH-- or .dbd.N--; R.sup.1 is selected from the group consisting of aminoacyl, acylamino, carboxyl, carboxyl ester, aryl, and alkyl optionally substituted with hydroxy or halo; R.sup.2 is selected from the group consisting of hydrogen, optionally substituted alkyl, and aryl; R.sup.3 and R.sup.4, together with the nitrogen atom bound thereto, form a group selected from the group consisting of heterocyclic, substituted heterocyclic, heteroaryl, and substituted heteroaryl; R.sup.5 is -L-A.sup.1 where L is selected from the group consisting of --S(O).sub.r-- where r is one or two and C.sub.1 to C.sub.2 straight chain alkylene, optionally substituted with hydroxy, halo and acylamino; A.sup.1 is selected from the group consisting of aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl and substituted cycloalkyl; each R.sup.6 is independently selected from the group consisting of acyl, acylamino, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, amino, substituted amino, aminoacyl, aryl, substituted aryl, aryloxy, substituted aryloxy, carboxyl, carboxyl ester, cyano, cycloalkyl, substituted cycloalkyl, halo, heteroaryl, substituted heteroaryl, heteroaryloxy, substituted heteroaryloxy, heterocyclic, substituted heterocyclic, heterocyclyloxy, substituted heterocyclyloxy, hydroxy, nitro, thiol, alkylthio, substituted alkylthio, arylthio, substituted arylthio, heteroarylthio, and substituted heteroarylthio; p is equal to 1, 2 or 3; or pharmaceutically acceptable salts, esters and prodrugs thereof; with the proviso that when W is .dbd.N--, and A.sup.1 is substituted phenyl, said substituted phenyl does not include an ortho substituent of the formula -Q-NR.sup.7R.sup.8 where Q is a bond, C.sub.1 to C.sub.3 alkyl, C.sub.2 to C.sub.3 alkenyl, C.sub.2 to C.sub.3 alkynyl and R.sup.7 and R.sup.8 are independently C.sub.1 to C.sub.8 alkyl or C.sub.1 to C.sub.8 cycloalkyl optionally substituted with 1 to 3 substituents selected from the group consisting of hydroxy, halo, amino, cyano, nitro, C.sub.1 to C.sub.8 alkyl, C.sub.1 to C.sub.8 cycloalkyl, halo C.sub.1 to C.sub.8 alkyl, C.sub.1 to C.sub.8 alkoxy, halo C.sub.1 to C.sub.8 alkoxy, or R.sup.7 and R.sup.8 jointly with the nitrogen atom to which they are bound form an optionally substituted 3- to 7-membered heterocyclic or an optionally substituted 3- to 7-membered heteroaryl.

2. The compound of claim 1, wherein the compound is of formula IA: ##STR00093## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and p are as defined as in claim 1.

3. The compound of claim 1, wherein the compound is of formula IB: ##STR00094## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and p are as defined in claim 1.

4. A compound of formula IC: ##STR00095## wherein W is .dbd.CH-- or .dbd.N--; p is equal to 1, 2 or 3; R.sup.9 is alkyl or substituted alkyl; R.sup.11 and R.sup.12, together with the nitrogen atom bound thereto join to form a group selected from the group consisting of heterocyclic, substituted heterocyclic, heteroaryl, and substituted heteroaryl; R.sup.13 is -L.sup.1-A.sup.3, wherein L.sup.1 is --S(O).sub.r-- where r is 1 or 2 or C.sub.1 to C.sub.2 straight chain alkylene, and A.sup.3 is selected from the group consisting of aryl, substituted aryl, heteroaryl, and substituted heteroaryl; each R.sup.14 is independently selected from the group consisting of halo, C.sub.2 to C.sub.3 alkynyl, C.sub.2 to C.sub.3 alkenyl, C.sub.1 to C.sub.5 alkyl, C.sub.1 to C.sub.3 alkoxy, and phenyl; or pharmaceutically acceptable salts, esters or prodrugs thereof; with the proviso that when W is .dbd.N--, and A.sup.3 is substituted phenyl, said substituted phenyl does not include an ortho substituent of the formula -Q-NR.sup.7R.sup.8 where Q is a bond, C.sub.1 to C.sub.3 alkyl, C.sub.2 to C.sub.3 alkenyl, C.sub.2 to C.sub.3 alkynyl and R.sup.7 and R.sup.8 are independently C.sub.1 to C.sub.8 alkyl or C.sub.1 to C.sub.8 cycloalkyl optionally substituted with 1 to 3 substituents selected from the group consisting of hydroxy, halo, amino, cyano, nitro, C.sub.1 to C.sub.8 alkyl, C.sub.1 to C.sub.8 cycloalkyl, halo C.sub.1 to C.sub.8 alkyl, C.sub.1 to C.sub.8 alkoxy, halo C.sub.1 to C.sub.8 alkoxy, or R.sup.7 and R.sup.8 jointly with the nitrogen atom to which they are bound form an optionally substituted 3- to 7-membered heterocyclic or an optionally substituted 3- to 7-membered heteroaryl.

5. The compound of claim 1, wherein R.sup.1 is alkyl or aryl.

6. The compound of claim 5, wherein R.sup.1 is selected from the group consisting of ethyl, isopropyl, t-butyl, and phenyl.

7. The compound of claim 1, wherein R.sup.2 is hydrogen or methyl.

8. The compound of claim 1, wherein R.sup.3 and R.sup.4 together with the nitrogen atom attached thereto join to form a substituted heterocyclic group.

9. The compound of claim 8, wherein the heterocyclic group is 2-aminoethyl-5-methyl-8-oxo-7H-quinazolin-1-yl.

10. The compound of claim 1, wherein L is --SO.sub.2-- or --CH.sub.2-- and A.sup.1 is optionally substituted aryl.

11. The compound of claim 1, wherein R.sup.5 is selected from the group consisting of 2,4-difluorobenzyl; 2-methylbenzyl; 3-(methylamido)benzyl; 3,5-difluorobenzyl; 3-chlorobenzyl; 3-fluorobenzyl; 3-hydroxybenzyl; 3-methylbenzyl; 4-chlorobenzyl; 4-methylbenzyl; benzyl; and thiazol-4-ylmethyl.

12. The compound of claim 1, wherein R.sup.5 groups are selected from the group consisting of: 3-(methylamido)benzyl, 3,5-difluorobenzyl; 3-chlorobenzyl; 3-fluorobenzyl; 3-hydroxybenzyl; 4-chlorobenzyl; and benzyl.

13. The compound of claim 1, wherein p is 1.

14. The compound of claim 13, wherein R.sup.6 is selected from the group consisting of propargyl; bromo; --CF.sub.3; chloro; ethyl; ethynyl; fluoro; methoxy; methyl; phenyl; and vinyl.

15. The compound of claim 1, wherein R.sup.6 is selected from the group consisting of bromo; chloro; ethyl; methoxy; methyl; propargyl; vinyl; fluoro; and phenyl.

16. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

17. The composition of claim 16 further comprising at least one additional agent for the treatment of cancer.

18. The composition of claim 17, wherein the additional agent for the treatment of cancer is selected from the group consisting of irinotecan, topotecan, gemcitabine, imatinib, trastuzumab, 5-fluorouracil, leucovorin, carboplatin, cisplatin, docetaxel, paclitaxel, tezacitabine, cyclophosphamide, vinca alkaloids, anthracyclines, rituximab, and trastuzumab.

19. A compound of formula IA': ##STR00096## wherein: R.sup.1 is selected from the group consisting of aminoacyl, acylamino, carboxyl, carboxyl ester, aryl, and alkyl optionally substituted with hydroxy or halo; R.sup.2 is selected from the group consisting of hydrogen, optionally substituted alkyl, and aryl; R.sup.3 and R.sup.4, together with the nitrogen atom bound thereto, form a group selected from the group consisting of heterocyclic, substituted heterocyclic, heteroaryl, and substituted heteroaryl; R.sup.5 is selected from the group consisting of 2,4-difluorobenzyl; 2-methylbenzyl; 3-(methylamido)benzyl; 3,5-difluorobenzyl; 3-chlorobenzyl; 3-fluorobenzyl; 3-hydroxybenzyl; 3-methylbenzyl; 4-chlorobenzyl; 4-methylbenzyl; benzyl; and thiazol-4-ylmethyl; each R.sup.6 is independently selected from the group consisting of acyl, acylamino, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, amino, substituted amino, aminoacyl, aryl, substituted aryl, aryloxy, substituted aryloxy, carboxyl, carboxyl ester, cyano, cycloalkyl, substituted cycloalkyl, halo, heteroaryl, substituted heteroaryl, heteroaryloxy, substituted heteroaryloxy, heterocyclic, substituted heterocyclic, heterocyclyloxy, substituted heterocyclyloxy, hydroxy, nitro, thiol, alkylthio, substituted alkylthio, arylthio, substituted arylthio, heteroarylthio, and substituted heteroarylthio; p is equal to 0, 1, 2 or 3; or pharmaceutically acceptable salts, esters and prodrugs thereof.

20. A compound of formula IA': ##STR00097## wherein: R.sup.1 is selected from the group consisting of ethyl, isopropyl, t-butyl, and phenyl; R.sup.2 is selected from the group consisting of hydrogen, optionally substituted alkyl, and aryl; R.sup.3 and R.sup.4, together with the nitrogen atom bound thereto, form a group selected from the group consisting of heterocyclic, substituted heterocyclic, heteroaryl, and substituted heteroaryl; R.sup.5 is -L-A.sup.1 where L is selected from the group consisting of --S(O).sub.r-- where r is one or two and C.sub.1 to C.sub.2 straight chain alkylene, optionally substituted with hydroxy, halo and acylamino; A.sup.1 is phenyl or substituted phenyl; each R.sup.6 is independently selected from the group consisting of acyl, acylamino, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, amino, substituted amino, aminoacyl, aryl, substituted aryl, aryloxy, substituted aryloxy, carboxyl, carboxyl ester, cyano, cycloalkyl, substituted cycloalkyl, halo, heteroaryl, substituted heteroaryl, heteroaryloxy, substituted heteroaryloxy, heterocyclic, substituted heterocyclic, heterocylyloxy, substituted heterocyclyloxy, hydroxy, nitro, thiol, alkylthio, substituted alkylthio, arylthio, substituted arylthio, heteroarylthio, and substituted heteroarylthio; p is equal to 0, 1, 2 or 3; or pharmaceutically acceptable salts, esters and prodrugs thereof; with the proviso that when A.sup.1 is substituted phenyl, said substituted phenyl does not include an ortho substituent of the formula -Q-NR.sup.7R.sup.8 where Q is a bond, C.sub.1 to C.sub.3 alkyl, C.sub.2 to C.sub.3 alkenyl, C.sub.2 to C.sub.3 alkynyl and R.sup.7 and R.sup.8 are independently C.sub.1 to C.sub.8 alkyl or C.sub.1 to C.sub.8 cycloalkyl optionally substituted with 1 to 3 substituents selected from the group consisting of hydroxy, halo, amino, cyano, nitro, C.sub.1 to C.sub.8 alkyl, C.sub.1 to C.sub.8 cycloalkyl, halo C.sub.1 to C.sub.8 alkyl, C.sub.1 to C.sub.8 alkoxy, halo C.sub.1 to C.sub.8 alkoxy, or R.sup.7 and R.sup.8 jointly with the nitrogen atom to which they are bound form an optionally substituted 3- to 7-membered heterocyclic or an optionally substituted 3- to 7-membered heteroaryl.

21. The compound of claim 19, wherein R.sup.2 is hydrogen or methyl.

22. The compound of claim 19, wherein R.sup.3 and R.sup.4 together with the nitrogen atom attached thereto join to form a substituted heterocyclic group.

23. The compound of claim 22, wherein the heterocyclic group is 2-aminoethyl-5-methyl-8-oxo-7H-quinazolin-1-yl.

24. The compound of claim 19, wherein R.sup.5 groups are selected from the group consisting of: 3-(methylamido)benzyl; 3,5-difluorobenzyl; 3-chlorobenzyl; 3-fluorobenzyl; 3-hydroxybenzyl; 4-chlorobenzyl; and benzyl.

25. A compound of formula IA': ##STR00098## wherein: R.sup.1 is selected from the group consisting of aminoacyl, acylamino, carboxyl, carboxyl ester, aryl, and alkyl optionally substituted with hydroxy or halo; R.sup.2 is selected from the group consisting of hydrogen, optionally substituted alkyl, and aryl; R.sup.3 and R.sup.4, together with the nitrogen atom bound thereto, form a group selected from the group consisting of heterocyclic, substituted heterocyclic, heteroaryl, and substituted heteroaryl; R.sup.5 is -L-A.sup.1 where L is selected from the group consisting of --S(O).sub.r-- where r is one or two and C.sub.1 to C.sub.2 straight chain alkylene, optionally substituted with hydroxy, halo and acylamino; A.sup.1 is phenyl or substituted phenyl; each R.sup.6 is independently selected from the group consisting of acyl, acylamino, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, amino, substituted amino, aminoacyl, aryl, substituted aryl, aryloxy, substituted aryloxy, carboxyl, carboxyl ester, cyano, cycloalkyl, substituted cycloalkyl, halo, heteroaryl, substituted heteroaryl, heteroaryloxy, substituted heteroaryloxy, heterocyclic, substituted heterocyclic, heterocyclyloxy, substituted heterocyclyloxy, hydroxy, nitro, thiol, alkylthio, substituted alkylthio, arylthio, substituted arylthio, heteroarylthio, and substituted heteroarylthio; p is 1; or pharmaceutically acceptable salts, esters and prodrugs thereof; with the proviso that when A.sup.1 is substituted phenyl, said substituted phenyl does not include an ortho substituent of the formula -Q-NR.sup.7R.sup.8 where Q is a bond, C.sub.1 to C.sub.3 alkyl, C.sub.2 to C.sub.3 alkenyl, C.sub.2 to C.sub.3 alkynyl and R.sup.7 and R.sup.8 are independently C.sub.1 to C.sub.8 alkyl or C.sub.1 to C.sub.8 cycloalkyl optionally substituted with 1 to 3 substituents selected from the group consisting of hydroxy, halo, amino, cyano, nitro, C.sub.1 to C.sub.8 alkyl, C.sub.1 to C.sub.8 cycloalkyl, halo C.sub.1 to C.sub.8 alkyl, C.sub.1 to C.sub.8 alkoxy, halo C.sub.1 to C.sub.8 alkoxy, or R.sup.7 and R.sup.8 jointly with the nitrogen atom to which they are bound form an optionally substituted 3- to 7-membered heterocyclic or an optionally substituted 3- to 7-membered heteroaryl.

26. The compound of claim 19, wherein R.sup.6 is selected from the group consisting of propargyl; bromo; --CF.sub.3; chloro; ethyl; ethynyl; fluoro; methoxy; methyl; phenyl; and vinyl.

27. The compound of claim 19, wherein R.sup.6 is selected from the group consisting of bromo; chloro; ethyl; methoxy; methyl; propargyl; vinyl; fluoro; and phenyl.

28. The compound of claim 19, wherein p is 0.

29. A compound of formula IC': ##STR00099## wherein p is equal to 0, 1, 2 or 3; R.sup.9 is alkyl or substituted alkyl; R.sup.11 and R.sup.12, together with the nitrogen atom bound thereto, join to form a group selected from the group consisting of heterocyclic, substituted heterocyclic, heteroaryl, and substituted heteroaryl; R.sup.13 is -L.sup.1-A.sup.3, wherein L.sup.1 is --S(O).sub.r-- where r is 1 or 2 or C.sub.1 to C.sub.2 straight chain alkylene, and A.sup.3 is phenyl or substituted phenyl; each R.sup.14 is independently selected from the group consisting of halo, C.sub.2 to C.sub.3 alkynyl, C.sub.2 to C.sub.3 alkenyl, C.sub.1 to C.sub.5 alkyl, C.sub.1 to C.sub.3 alkoxy, and phenyl; or pharmaceutically acceptable salts, esters or prodrugs thereof; with the proviso that when A.sup.3 is substituted phenyl, said substituted phenyl does not include an ortho substituent of the formula -Q-NR.sup.7R.sup.8 where Q is a bond, C.sub.1 to C.sub.3 alkyl, C.sub.2 to C.sub.3 alkenyl, C.sub.2 to C.sub.3 alkynyl and R.sup.7 and R.sup.8 are independently C.sub.1 to C.sub.8 alkyl or C.sub.1 to C.sub.8 cycloalkyl optionally substituted with 1 to 3 substituents selected from the group consisting of hydroxy, halo, amino, cyano, nitro, C.sub.1 to C.sub.8 alkyl, C.sub.1 to C.sub.8 cycloalkyl, halo C.sub.1 to C.sub.8 alkyl, C.sub.1 to C.sub.8 alkoxy, halo C.sub.1 to C.sub.8 alkoxy, or R.sup.7 and R.sup.8 jointly with the nitrogen atom to which they are bound form an optionally substituted 3- to 7-membered heterocyclic or an optionally substituted 3- to 7-membered heteroaryl.

Summary for Patent:   Try a Free Trial

PCT Information
PCT FiledOctober 14, 2005PCT Application Number:PCT/US2005/036803
PCT Publication Date:May 11, 2006PCT Publication Number:WO2006/049835

Details for Patent 8,008,335

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab VIAL 103705 001 1997-11-26   Try a Free Trial Novartis Vaccines and Diagnostics, Inc. (Emeryville, CA) 2024-10-19 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Try a Free Trial Novartis Vaccines and Diagnostics, Inc. (Emeryville, CA) 2024-10-19 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Baxter
Fuji
Medtronic
Farmers Insurance
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.